Last reviewed · How we verify
Neuroprotection
Neuroprotection is a Small molecule drug developed by The Central and Eastern European Gynecologic Oncology Group. It is currently in Phase 3 development.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Neuroprotection |
|---|---|
| Sponsor | The Central and Eastern European Gynecologic Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Safely Quenching Complement in Stroke Survivors (PHASE1)
- Minocycline in Stroke Study at Maimonides (PHASE2, PHASE3)
- Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest (NA)
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
- Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke (NA)
- Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis (PHASE2)
- Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT
- Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuroprotection CI brief — competitive landscape report
- Neuroprotection updates RSS · CI watch RSS
- The Central and Eastern European Gynecologic Oncology Group portfolio CI
Frequently asked questions about Neuroprotection
What is Neuroprotection?
Who makes Neuroprotection?
What development phase is Neuroprotection in?
Related
- Manufacturer: The Central and Eastern European Gynecologic Oncology Group — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing